Allergy Therapeutics Plc

Allergy Therapeutics Plc

Allergy Therapeutics Plc

Overview
Date Founded

2004

Headquarters

Dominion Way,Worthing, West Sussex BN14 8SA

Type of Company

Public

Employees (Worldwide)

506

Industries

Pharmaceuticals
Other Manufacturing
IT Consulting & Services
Medical Support Services
Hospitals & Patient Services

Company Description

Allergy Therapeutics Plc is a biotechnology company. It focuses on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. It operates through the following geographical segments: Central Europe, Southern Europe, the United Kingdom, and the Rest of the World. The company was founded by Keith Iain Carter in 1998 and is headquartered in Worthing, the United Kingdom.

Executives & Employees

Chief Executive Officer

Chief Finance Officer

Director, Business Development

Director, Supply Operations Site

Secretary & Director-Corporate Governance

Chief Scientific Officer

Head-Human Resources

Head of Clinical Science

Group Financial Controller

Director-International Medical

Board of Directors

Brand Manager at Johnson & Johnson Ltd.

Associate Clinical Professor, Division of Pulmonary & Critical Care Medicine at UC Davis Health System

Chief Executive Officer at Allergy Therapeutics Plc

Former Finance Director at Food & Drink Group Plc

Former Chief Financial Officer, Secretary & Executive Director at Advanced Medical Solutions Group Plc

Chief Finance Officer at Allergy Therapeutics Plc

Vice President at Abbott International LLC

Senior Vice President & Head-Global Commercial Strategy at ViiV Healthcare Ltd.

Paths to Allergy Therapeutics Plc
Potential Connections via
Relationship Science
You
Allergy Therapeutics Plc
Owners & Shareholders
Details Hidden

Hauck & Aufhäuser uses an active asset management style in providing their management services. They utilize a fundamental and quantitative analysis for their investment decisions.

Details Hidden

Teviot is an active, value manager which performs in-house analysis, seeking to identify small listed companies trading below their intrinsic value to deliver superior returns.The firm employs a bottom-up approach based on the research and origination of their own investment ideas. They evaluate the core fundamentals of investee companies including management and governance, the strategic positioning of the business in the context of the broader market, earnings and cashflows. There is an asset allocation overlay and the portfolio is constructed with an appreciation of risk at the portfolio level.Teviot uses independent industry data to inform their investment decisions. Their investment universe is framed by the Numis Smaller Companies Index (excl. Investment Companies, including AIM) and includes UK listed companies up to a market-cap of circa 1.4 billion GBP. They invest in a select number of the best value opportunities across this universe.

Details Hidden

Amber Capital has a philosophy of shareholder engagement with a long-term, value-oriented approach. The Investment Team focuses on European countries where it may invest “like locals”, drawing on resources committed to developing a deep understanding of the legal, socio-political and cultural nuances of these markets. Key to Amber Capital’s investment approach is the combination of value-oriented, bottom-up fundamental analysis and a focus on catalyst-driven situations. The strategies and instruments employed vary based on the specific fund, investment mandate and point in the market cycle.

Recent Transactions
Details Hidden

Allergy Therapeutics Plc issued GBP Ordinary Shares

Details Hidden

Allergy Therapeutics Plc purchases Alerpharma SA

Details Hidden

Allergy Therapeutics Plc issued GBP Ordinary Shares

Transaction Advisors
Investment Advisor

Advised onAllergy Therapeutics Plc issued GBP Ordinary Shares

Investment Advisor

Advised onAllergy Therapeutics Plc issued GBP Ordinary Shares

Broker

Advised onAllergy Therapeutics Plc issued GBP Ordinary Shares

Legal Advisor

Advised onAllergy Therapeutics Plc purchases Alerpharma SA

Chair, International Employment Practice Group

Advised onAllergy Therapeutics Plc purchases Alerpharma SA

Associate

Advised onAllergy Therapeutics Plc purchases Alerpharma SA

Advisors & Consultants
Publicist

Head of Healthcare & Corporate Advisory-Corporate Finance at Panmure Gordon (UK) Ltd.

Publicist

Professional at Numis Securities Limited

Publicist

Corporate Broking at Panmure Gordon (UK) Ltd.

Key Stats and Financials As of 2021
Market Capitalization
$316M
Total Enterprise Value
$193M
Earnings Per Share
$0.01
Enterprise Value / Sales
1.66x
TEVNet Income
48.53x
Debt TEV
0.08x
EBITDAMargin
8.03%
Enterprise Value EBITDAOperating
20.67x
Three Year Compounded Annual Growth Rate Of Revenue
7.26%
Revenue
$116M
Net Profit
$3.99M
Total Debt
$15.4M
Total Equity
$67M
EBITDA
$9.36M
Suppliers
Stallergenes Greer Ltd. Other Business & Consulting Services | London, United Kingdom

Stallergenes Greer Ltd. is a healthcare company, which engages in the development and commercialization of allergy immunotherapy products and services. Its products include sublingual products, subcutaneous products, and veterinary products. The company was founded on December 6, 2013 and headquartered in London, the United Kingdom.

Saiba GmbH Biotechnology | Rämismühle, Switzerland

Saiba GmbH is a Swiss private company located in Rämismühle that develops cutting-edge therapeutic and prophylactic vaccines.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Allergy Therapeutics Plc. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Allergy Therapeutics Plc's profile does not indicate a business or promotional relationship of any kind between RelSci and Allergy Therapeutics Plc.